Cancer Research and Treatment

Original Articles

Gastrointestinal cancer

Prognostic Evaluation and Survival Prediction for Combined Hepatocellular-Cholangiocarcinoma Following Hepatectomy: Seok-Joo Chun, Yu Jung Jung, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Kyoung Bun Lee, Hyun-Cheol Kang, Eui Kyu Chie, Kyung Su Kim; Cancer Res Treat. 2025;57(1):229-239. Published online July 3, 2024; DOI: https://doi.org/10.4143/crt.2024.176

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to assess prognostic factors associated with combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and to predict 5-year survival based on these factors.
Materials and Methods
Patients who underwent definitive hepatectomy from 2006 to 2022 at a single institution was retrospectively analyzed. Inclusion criteria involved a pathologically confirmed diagnosis of cHCC-CCA.
Results
A total of 80 patients with diagnosed cHCC-CCA were included in the analysis. The median progression-free survival was 15.6 months, while distant metastasis-free survival (DMFS), hepatic progression-free survival, and overall survival (OS) were 50.8, 21.5, and 85.1 months, respectively. In 52 cases of recurrence, intrahepatic recurrence was the most common initial recurrence (34/52), with distant metastasis in 17 cases. Factors associated with poor DMFS included tumor necrosis, lymphovascular invasion (LVI), perineural invasion, and histologic compact type. Postoperative carbohydrate antigen 19-9, tumor necrosis, LVI, and close/positive margin were associated with poor OS. LVI emerged as a key factor affecting both DMFS and OS, with a 5-year OS of 93.3% for patients without LVI compared to 35.8% with LVI. Based on these factors, a nomogram predicting 3-year and 5-year DMFS and OS was developed, demonstrating high concordance with actual survival in the cohort (Harrell C-index 0.809 for OS, 0.801 for DMFS, respectively).
Conclusion
The prognosis of cHCC-CCA is notably poor when combined with LVI. Given the significant impact of adverse features, accurate outcome prediction is crucial. Moreover, consideration of adjuvant therapy may be warranted for patients exhibiting poor survival and increased risk of local recurrence or distant metastasis.

Citations

Citations to this article as recorded by

Combined hepatocellular-cholangiocarcinoma in a middle-aged patient: A case report and review of therapeutic approaches
Chen Guo, Yutao He, Zhitian Shi, Lin Wang
International Journal of Surgery Case Reports.2025; 129: 111165. CrossRef

2,228 View
107 Download
1 Web of Science
1 Crossref

Gynecologic cancer

Image-Guided Versus Conventional Brachytherapy for Locally Advanced Cervical Cancer: Experience of Single Institution with the Same Practitioner and Time Period: Tae Hoon Lee, Kyung Su Kim, Hak Jae Kim, Chang Heon Choi, Seonghee Kang, Keun-Yong Eom, Chan Woo Wee, Yong Sang Song, Noh Hyun Park, Jae-Weon Kim, Hyun Hoon Chung, Hee Seung Kim, Maria Lee, Hyun-Cheol Kang; Cancer Res Treat. 2023;55(1):258-269. Published online August 10, 2022; DOI: https://doi.org/10.4143/crt.2022.418

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.
Materials and Methods
Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.
Results
The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.
Conclusion
IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities.

Citations

Citations to this article as recorded by

Cisplatin

Reactions Weekly.2023; 1947(1): 125. CrossRef
A Mixed Methods Study to Implement the Synergy Tool and Evaluate Its Impact on Long-Term Care Residents
Farinaz Havaei, Francis Kobekyaa, Andy Ma, Maura MacPhee, Wei Zhang, Megan Kaulius, Bahar Ahmadi, Sheila Boamah, Adam Easterbrook, Amy Salmon
Healthcare.2023; 11(15): 2187. CrossRef

5,448 View
125 Download
1 Web of Science
2 Crossref

Breast cancer

The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12): Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, Ji Ho Nam, Won Sup Yoon, Jin Hee Kim, Jihye Cha, Yoon Kyeong Oh, In Ah Kim; Cancer Res Treat. 2022;54(4):1121-1129. Published online December 31, 2021; DOI: https://doi.org/10.4143/crt.2021.1083

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea.
Materials and Methods
We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12.5 months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients).
Results
Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance.
Conclusion
The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.

Citations

Citations to this article as recorded by

Comparison of initial and sequential salvage brain-directed treatment in patients with 1–4 vs. 5–10 brain metastases from breast cancer (KROG 16–12)
Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki C
Breast Cancer Research and Treatment.2023; 200(1): 37. CrossRef

6,876 View
189 Download
1 Web of Science
1 Crossref

Special Article

Who Will Benefit from Charged-Particle Therapy?: Kyung Su Kim, Hong-Gyun Wu; Cancer Res Treat. 2021;53(3):621-634. Published online June 21, 2021; DOI: https://doi.org/10.4143/crt.2021.299

Abstract PDF PubReader ePub

Charged-particle therapy (CPT) such as proton beam therapy (PBT) and carbon-ion radiotherapy (CIRT) exhibit substantial physical and biological advantages compared to conventional photon radiotherapy. As it can reduce the amount of radiation irradiated in the normal organ, CPT has been mainly applied to pediatric cancer and radioresistent tumors in the eloquent area. Although there is a possibility of greater benefits, high set-up cost and dearth of high level of clinical evidence hinder wide applications of CPT. This review aims to present recent clinical results of PBT and CIRT in selected diseases focusing on possible indications of CPT. We also discussed how clinical studies are conducted to increase the number of patients who can benefit from CPT despite its high cost.

Citations

Citations to this article as recorded by

Cost-effectiveness analysis for multi adverse events of proton beam therapy for pediatric medulloblastoma in Japan
Takaaki Yoshimura, Yasuhiro Morii, Honoka Tamori, Ryuki Kita, Takayuki Hashimoto, Hidefumi Aoyama, Katsuhiko Ogasawara
Journal of Radiation Research.2025; 66(1): 31. CrossRef
Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy
Lihui Xuan, Chenjun Bai, Zhao Ju, Jinhua Luo, Hua Guan, Ping-Kun Zhou, Ruixue Huang
Cytokine & Growth Factor Reviews.2024; 75: 1. CrossRef
Radioresistance-related gene signatures identified by transcriptomics characterize the prognosis and immune landscape of pancreatic cancer patients
Dandan Wang, Jun Cao, Yanhui Chen, Lisha Zhang, Chan Zhou, Litao Huang, Yanliang Chen
BMC Cancer.2024;[Epub] CrossRef
Avances en radioterapia para el tratamiento multimodal del cáncer
Alejandro González-Motta, Gabriela Negrete-Tobar, Iván Bobadilla
Medicina.2024; 46(2): 566. CrossRef
Cellular irradiations with laser-driven carbon ions at ultra-high dose rates
Pankaj Chaudhary, Giuliana Milluzzo, Aodhan McIlvenny, Hamad Ahmed, Aaron McMurray, Carla Maiorino, Kathryn Polin, Lorenzo Romagnani, Domenico Doria, Stephen J McMahon, Stanley W Botchway, Pattathil P Rajeev, Kevin M Prise, Marco Borghesi
Physics in Medicine & Biology.2023; 68(2): 025015. CrossRef
Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis
Yanliang Chen, Hongtao Luo, Ruifeng Liu, Mingyu Tan, Qian Wang, Xun Wu, Tianqi Du, Zhiqiang Liu, Shilong Sun, Qiuning Zhang, Xiaohu Wang
Radiation Oncology.2023;[Epub] CrossRef
Particle radiotherapy in the era of radioimmunotherapy
Zihan Zhou, Bingjie Guan, Huang Xia, Rong Zheng, Benhua Xu
Cancer Letters.2023; 567: 216268. CrossRef
The Rise of Particle Beam Therapy: Are We Ready for The Potential Game-Changer?
Eui Kyu Chie, Yong Chan Ahn
Cancer Research and Treatment.2021; 53(3): 609. CrossRef

7,930 View
243 Download
7 Web of Science
8 Crossref

Meta-Analysis

Impact of Resection Margin Distance on Survival of Pancreatic Cancer: A Systematic Review and Meta-Analysis: Kyung Su Kim, Jeanny Kwon, Kyubo Kim, Eui Kyu Chie; Cancer Res Treat. 2017;49(3):824-833. Published online August 26, 2016; DOI: https://doi.org/10.4143/crt.2016.336

Abstract PDF PubReader ePub

Purpose
While curative resection is the only chance of cure in pancreatic cancer, controversies exist about the impact of surgical margin status on survival. Non-standardized pathologic report and different criteria on the R1 status made it difficult to implicate adjuvant therapy after resection based on the margin status. We evaluated the influence of resection margins on survival by meta-analysis.
Materials and Methods
We thoroughly searched electronic databases of PubMed, EMBASE, and Cochrane Library. We included studies reporting survival outcomeswith different margin status: involved margin (R0 mm), margin clearance with ≤ 1 mm (R0-1 mm), and margin with > 1 mm (R>1 mm). Hazard ratio (HR) for overall survival was extracted, and a random-effects model was used for pooled analysis.
Results
A total of eight retrospective studies involving 1,932 patients were included. Pooled HR for overall survival showed that patients with R>1 mm had reduced risk of death than those with R0-1 mm (HR, 0.74; 95% confidence interval [CI], 0.61 to 0.88; p=0.001). In addition, patients with R0-1 mm had reduced risk of death than those with R0 mm (HR, 0.81; 95% CI, 0.72 to 0.91; p < 0.001). There was no heterogeneity between the included studies (I 2 index, 42% and 0%; p=0.10 and p=0.82, respectively).
Conclusion
Our results suggest that stratification of the patients based on margin status is warranted in the clinical trials assessing the role of adjuvant treatment for pancreatic cancer.

Citations

Citations to this article as recorded by

Stapled Arterial Divestment in Surgery for Locally Advanced Pancreatic Cancer
Krishna Kotecha, Juanita Chui, Kai Brown, Anubhav Mittal, Jaswinder Samra
Journal of Surgical Oncology.2025; 131(5): 851. CrossRef
An R0 resection margin does improve overall survival after PDAC resection– real-world evidence from 6.000 cases from the German Cancer Registry Group
Lennart von Fritsch, Jannis Duhn, Thaer S.A. Abdalla, Kim C. Honselmann, Louisa Bolm, Rüdiger Braun, Markus Kist, Hryhoriy Lapshyn, Sylke Ruth Zeissig, Monika Klinkhammer-Schalke, Kees Kleihues van Tol, Stanislav Litkevych, Fabian Reinwald, Andrea Sackman
European Journal of Surgical Oncology.2025; 51(6): 109693. CrossRef
Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of Perioperative Radiotherapy for Patients with Pancreatic Ductal Adenocarcinoma: An Updated Multicenter Retrospective Cohort Study
Won-Gun Yun, Wooil Kwon, Hee Ju Sohn, Youngmin Han, Yoon Soo Chae, Hye-Sol Jung, Young Jae Cho, Chang-Sup Lim, Yoo-Seok Yoon, Jin-Young Jang
Annals of Surgical Oncology.2025; 32(7): 5110. CrossRef
Clinical outcomes in borderline and locally advanced pancreatic cancer with the addition of low-dose-rate brachytherapy to standard of care therapy
Ross J. Taylor, Gregory J. Matthews, Robert H. Aseltine, Emma C. Fields
Brachytherapy.2024; 23(3): 355. CrossRef
Laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) for adenocarcinoma of the body and tail of the pancreas — technical considerations with analysis of surgical outcomes
Maciej Borys, Michał Wysocki, Krystyna Gałązka, Maciej Stanek, Andrzej Budzyński
Langenbeck's Archives of Surgery.2024;[Epub] CrossRef
Neoadjuvant treatment for pancreatic cancer: Controversies and advances
Douglas Dias e Silva, Vincent Chung
Cancer Treatment and Research Communications.2024; 39: 100804. CrossRef
Evaluation of local recurrence after pancreaticoduodenectomy for borderline resectable pancreatic head cancer with neoadjuvant chemotherapy: Can the resection level change after chemotherapy?
Kosuke Kobayashi, Yoshihiro Ono, Shoki Sato, Tomotaka Kato, Atsushi Oba, Takafumi Sato, Hiromichi Ito, Yosuke Inoue, Manabu Takamatsu, Akio Saiura, Yu Takahashi
Surgery.2023; 173(5): 1220. CrossRef
Rhabdoid carcinoma of the pancreas: A rare cause of unidentified carcinomas of the pancreas
Ayoub Madani, Anass Derkaoui, Tarik Deflaoui, Hanane El Aggari, Nadir Miry, Benani Amal, Rachid Jabi, Mohamed Bouziane
Surgery Open Digestive Advance.2023; 9: 100076. CrossRef
Prognostic significance of margin clearance in pancreaticoduodenectomy specimens with pancreatic ductal adenocarcinoma in a Danish population-based nationwide study
Trine Aaquist, Claus W. Fristrup, Jane P. Hasselby, Stephen Hamilton-Dutoit, Mikkel Eld, Per Pfeiffer, Michael B. Mortensen, Sönke Detlefsen
HPB.2023; 25(7): 826. CrossRef
Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) — Results from the Multicentre Indian Pancreatic & Periampullary Adenocarcinoma Project (MIPPAP) Study
Vikram Chaudhari, Anant Ramaswamy, Sujay Srinivas, Ajit Agarwal, Ramakrishnan Ayloor Seshadri, Vineet Talwar, Prabhat Bhargava, Shaifali Goel, Smita Kayal, Pradeep Rebala, Bharat Prajapati, Devendra Parikh, Jagdish Kothari, Ramesh M. Ch, Jacob Mathew Kada
Journal of Gastrointestinal Cancer.2023; 54(4): 1338. CrossRef
Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9
Dengfeng Li, Qing Peng, Leyao Wang, Wei Cai, Meng Liang, Siyun Liu, Xiaohong Ma, Xinming Zhao
European Radiology.2023; 34(1): 509. CrossRef
Predicting resection margin status of pancreatic neuroendocrine tumors on CT: performance of NCCN resectability criteria
Dong Hwan Kim, Bohyun Kim, Dong Jin Chung, Kyung Ah Kim, Su Lim Lee, Moon Hyung Choi, Hokun Kim, Sung Eun Rha
The British Journal of Radiology.2023;[Epub] CrossRef
Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer
Sam Z. Thalji, Deemantha Fernando, Kulwinder S. Dua, Srivats Madhavan, Phillip Chisholm, Zachary L. Smith, Mohammed Aldakkak, Kathleen K. Christians, Callisia N. Clarke, Ben George, Mandana Kamgar, Beth A. Erickson, William A. Hall, Douglas B. Evans, Susa
Annals of Surgery.2023; 278(6): e1224. CrossRef
Lymph Node Stations of Pancreas Which Are Identified in Real Color Sectioned Images of a Cadaver With Pancreatic Cancer
Chung Yoh Kim, Yongwook Jung, Jin Seo Park
Journal of Korean Medical Science.2023;[Epub] CrossRef
CivaSheet intraoperative radiation therapy for pancreatic cancer
Ross J. Taylor, Dorin Todor, Brian J. Kaplan, Weston Stover, Emma C. Fields
Brachytherapy.2022; 21(2): 255. CrossRef
Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy
Soomin Ahn, Jong-chan Lee, Jaihwan Kim, Young Hoon Kim, Yoo-Seok Yoon, Ho-Seong Han, Haeryoung Kim, Jin-Hyeok Hwang
Gut and Liver.2022; 16(1): 129. CrossRef
Preoperative Serum Carbohydrate Antigen 19-9 Levels Cannot Predict the Surgical Resectability of Pancreatic Cancer: A Meta-Analysis
Márton Benke, Nelli Farkas, Péter Hegyi, Benedek Tinusz, Patrícia Sarlós, Bálint Erőss, Kata Szemes, Nóra Vörhendi, Zsolt Szakács, Ákos Szücs
Pathology and Oncology Research.2022;[Epub] CrossRef
Neoadjuvant therapy in pancreatic ductal adenocarcinoma: A competing risk analysis
Carlo Alberto Pacilio, Elisa Grassi, Andrea Gardini, Francesca Fappiano, Alessandro Passardi, Giovanni Luca Frassineti, Stefano Tamberi, Giorgio Ercolani
Surgical Practice.2022; 26(3): 155. CrossRef
Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma
Vincent Dunet, Nermin Halkic, Christine Sempoux, Nicolas Demartines, Michael Montemurro, John O. Prior, Sabine Schmidt
European Radiology.2021; 31(2): 992. CrossRef
First report on the feasibility of a permanently implantable uni-directional planar low dose rate brachytherapy sheet for patients with resectable or borderline resectable pancreatic cancer
Joshua B. Dault, Dorin Todor, Brian J. Kaplan, Jennifer L. Myers, Emma C. Fields
Brachytherapy.2021; 20(1): 207. CrossRef
Periarterial divestment in pancreatic cancer surgery
Markus K. Diener, André L. Mihaljevic, Oliver Strobel, Martin Loos, Thomas Schmidt, Martin Schneider, Christoph Berchtold, Arianeb Mehrabi, Beat P. Müller-Stich, Kuirong Jiang, John P. Neoptolemos, Thilo Hackert, Yi Miao, Markus W. Büchler
Surgery.2021; 169(5): 1019. CrossRef
Advances and challenges of neoadjuvant therapy in pancreatic cancer
Yang Yu, Peng Zheng, Yajing Chen, Bofang Wang, Maswikiti Ewetse Paul, Pengxian Tao, Dengfeng Wang, Haiyuan Li, Baohong Gu, Lei Gao, Dan Wang, Hao Chen
Asia-Pacific Journal of Clinical Oncology.2021; 17(6): 425. CrossRef
R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma
Stefano Crippa, Fabio Giannone, Marco Schiavo Lena, Giulio Belfiori, Stefano Partelli, Domenico Tamburrino, Roberto Delpini, Michele Pagnanelli, Nicolo Pecorelli, Gianpaolo Balzano, Claudio Doglioni, Massimo Falconi
Annals of Surgical Oncology.2021; 28(8): 4602. CrossRef
Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy
Ryan K. Schmocker, Daniel Delitto, Michael J. Wright, Ding Ding, John L. Cameron, Kelly J. Lafaro, William R. Burns, Christopher L. Wolfgang, Richard A. Burkhart, Jin He
Journal of the American College of Surgeons.2021; 232(4): 405. CrossRef
A Novel DNA Replication-Related Signature Predicting Recurrence After R0 Resection of Pancreatic Ductal Adenocarcinoma: Prognostic Value and Clinical Implications
Zengyu Feng, Kexian Li, Jianyao Lou, Mindi Ma, Yulian Wu, Chenghong Peng
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Impact of resection margin status on survival in advanced N stage pancreatic cancer – a multi-institutional analysis
Christian Teske, Richard Stimpel, Marius Distler, Susanne Merkel, Robert Grützmann, Louisa Bolm, Ulrich Wellner, Tobias Keck, Daniela E. Aust, Jürgen Weitz, Thilo Welsch
Langenbeck's Archives of Surgery.2021; 406(5): 1481. CrossRef
Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatectomy for left-sided pancreatic cancer: findings of a multicenter, retrospective, propensity score matching study
Hyung Sun Kim, Tae Ho Hong, Young-Kyoung You, Joon Seong Park, Dong Sup Yoon
Surgery Today.2021; 51(11): 1775. CrossRef
What do surgeons need to know about the mesopancreas
Eduardo de Souza M. Fernandes, Oliver Strobel, Camila Girão, Jose Maria A. Moraes-Junior, Orlando Jorge M. Torres
Langenbeck's Archives of Surgery.2021; 406(8): 2621. CrossRef
Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy
Michail Galanopoulos, Aris Doukatas, Filippos Gkeros, Nikos Viazis, Christos Liatsos
World Journal of Gastroenterology.2021; 27(24): 3568. CrossRef
Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021)
Yinmo Yang, Xueli Bai, Dapeng Bian, Shouwang Cai, Rufu Chen, Feng Cao, Menghua Dai, Chihua Fang, Deliang Fu, Chunlin Ge, Xiaochao Guo, Chunyi Hao, Jihui Hao, Heguang Huang, Zhixiang Jian, Gang Jin, Fei Li, Haimin Li, Shengping Li, Weiqin Li, Yixiong Li, H
Journal of Pancreatology.2021; 4(2): 49. CrossRef
Paraaortic dissection in “total mesopancreas excision” and “mesopancreas-first resection” pancreaticoduodenectomies for pancreatic cancer: Useless, optional, or necessary?A systematic review
Nadia Peparini
Surgical Oncology.2021; 38: 101639. CrossRef
Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy
Yuki Sunagawa, Masamichi Hayashi, Suguru Yamada, Hiroshi Tanabe, Keisuke Kurimoto, Nobutake Tanaka, Fuminori Sonohara, Yoshikuni Inokawa, Hideki Takami, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike, Yasuhiro Kodera
Clinical Epigenetics.2021;[Epub] CrossRef
Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Results (SEER) and Korea Tumor Registry System-Biliary Pancreas (KOTUS-BP)
Jae Seung Kang, Lydia Mok, Jin Seok Heo, In Woong Han, Sang Hyun Shin, Yoo-Seok Yoon, Ho-Seong Han, Dae Wook Hwang, Jae Hoon Lee, Woo Jung Lee, Sang Jae Park, Joon Seong Park, Yonghoon Kim, Huisong Lee, Young-Dong Yu, Jae Do Yang, Seung Eun Lee, Il Young
Gut and Liver.2021; 15(6): 912. CrossRef
Arterial Divestment and Resection in Post-neoadjuvant Pancreatic Adenocarcinoma
Yugal Limbu, Sujan Regmee, Roshan Ghimire, Dhiresh Kumar Maharjan, Prabin Bikram Thapa
Cureus.2021;[Epub] CrossRef
Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study
Marit Kalisvaart, Damian Broadhurst, Francesca Marcon, Rupaly Pande, Andrea Schlegel, Robert Sutcliffe, Ravi Marudanayagam, Darius Mirza, Nikolaos Chatzizacharias, Manuel Abradelo, Paolo Muiesan, John Isaac, Yuk T. Ma, Christopher McConville, Keith Robert
HPB.2020; 22(9): 1240. CrossRef
Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic cancer
Stefano Crippa, Giovanni Guarneri, Giulio Belfiori, Stefano Partelli, Michele Pagnanelli, Giulia Gasparini, Gianpaolo Balzano, Marco Schiavo Lena, Corrado Rubini, Claudio Doglioni, Giuseppe Zamboni, Massimo Falconi
European Journal of Surgical Oncology.2020; 46(8): 1524. CrossRef
Resection or repair of large peripancreatic arteries during robotic pancreatectomy
Emanuele F. Kauffmann, Niccolò Napoli, Concetta Cacace, Francesca Menonna, Fabio Vistoli, Gabriella Amorese, Ugo Boggi
Updates in Surgery.2020; 72(1): 145. CrossRef
In the Era of the Leeds Protocol: A Systematic Review and A Meta-Analysis on the Effect of Resection Margins on Survival Among Pancreatic Ductal Adenocarcinoma Patients
B. Kurlinkus, R. Ahola, E. Zwart, A. Halimi, B. S. Yilmaz, G. O. Ceyhan, J. Laukkarinen
Scandinavian Journal of Surgery.2020; 109(1): 11. CrossRef
Systematic Analysis of Accuracy in Predicting Complete Oncological Resection in Pancreatic Cancer Patients—Proposal of a New Simplified Borderline Resectability Definition
Louisa Bolm, Katharina Mueller, Katharina May, Stefan Sondermann, Ekaterina Petrova, Hryhoriy Lapshyn, Kim Christin Honselmann, Dirk Bausch, Sergii Zemskov, Peter Bronsert, Tobias Keck, Steffen Deichmann, Ulrich F. Wellner
Cancers.2020; 12(4): 882. CrossRef
Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study
Hongcheng Wang, Jiazhe Liu, Guanggai Xia, Shizhou Lei, Xiuyan Huang, Xinyu Huang
Scientific Reports.2020;[Epub] CrossRef
Circumferential resection margin (CRM) in pancreatic cancer
Lena Häberle, Irene Esposito
Surgery in Practice and Science.2020; 1: 100006. CrossRef
Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma
Tsengelmaa Jamiyan, Takayuki Shiraki, Yoshihiro Kurata, Masanori Ichinose, Keiichi Kubota, Yasuo Imai
World Journal of Surgical Oncology.2020;[Epub] CrossRef
Prognostic Implications of 18-FDG Positron Emission Tomography/Computed Tomography in Resectable Pancreatic Cancer
Cosimo Sperti, Alberto Friziero, Simone Serafini, Sergio Bissoli, Alberto Ponzoni, Andrea Grego, Emanuele Grego, Lucia Moletta
Journal of Clinical Medicine.2020; 9(7): 2169. CrossRef
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Aaron J. Grossberg, Linda C. Chu, Christopher R. Deig, Eliot K. Fishman, William L. Hwang, Anirban Maitra, Daniel L. Marks, Arnav Mehta, Nima Nabavizadeh, Diane M. Simeone, Colin D. Weekes, Charles R. Thomas
CA: A Cancer Journal for Clinicians.2020; 70(5): 375. CrossRef
Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma
Byoung Hyuck Kim, Kyubo Kim, Jin-Young Jang, Wooil Kwon, Hongbeom Kim, Kyung-Hun Lee, Do-Youn Oh, Haeryoung Kim, Kyung Bun Lee, Eui Kyu Chie
European Journal of Surgical Oncology.2020; 46(11): 2122. CrossRef
Pre‐operative diabetes mellitus does not worsen survival and post‐operative outcomes in Chinese patients undergoing resection for pancreatic adenocarcinoma
Adrian H. K. Yu, Albert C. Y. Chan
Surgical Practice.2020; 24(4): 132. CrossRef
Multiagent neoadjuvant chemotherapy and tumor response are associated with improved survival in pancreatic cancer
Nathan M. Bolton, Adam H. Maerz, Russell E. Brown, Mona Bansal, John S. Bolton, William C. Conway
HPB.2019; 21(4): 413. CrossRef
The learning curve for a surgeon in robot-assisted laparoscopic pancreaticoduodenectomy: a retrospective study in a high-volume pancreatic center
Tao Zhang, Zhi-Ming Zhao, Yuan-Xing Gao, Wan Yee Lau, Rong Liu
Surgical Endoscopy.2019; 33(9): 2927. CrossRef
Selecting chemotherapy for pancreatic cancer: Far away or so close?
Si Shi, Xianjun Yu
Seminars in Oncology.2019; 46(1): 39. CrossRef
Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I‐II pancreatic cancer
Sung Jun Ma, Gregory M. Hermann, Kavitha M. Prezzano, Lucas M. Serra, Austin J. Iovoli, Anurag K. Singh
Cancer Medicine.2019; 8(3): 939. CrossRef
Duktales Adenokarzinom des Pankreas
E. Gallmeier, T. M. Gress
Der Gastroenterologe.2019; 14(2): 131. CrossRef
Management of pancreatic head adenocarcinoma: From where to where?
Kemal Dolay, Fatma Umit Malya, Sami Akbulut
World Journal of Gastrointestinal Surgery.2019; 11(3): 143. CrossRef
Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma
Vincent P. Groot, Georgios Gemenetzis, Alex B. Blair, Roberto J. Rivero-Soto, Jun Yu, Ammar A. Javed, Richard A. Burkhart, Inne H. M. Borel Rinkes, I. Quintus Molenaar, John L. Cameron, Matthew J. Weiss, Christopher L. Wolfgang, Jin He
Annals of Surgery.2019; 269(6): 1154. CrossRef
A Prospective Clinical Trial to Determine the Effect of Intraoperative Ultrasound on Surgical Strategy and Resection Outcome in Patients with Pancreatic Cancer
Babs G. Sibinga Mulder, Shirin Feshtali, Arantza Fariña Sarasqueta, Alexander L. Vahrmeijer, Rutger-Jan Swijnenburg, Bert A. Bonsing, J. Sven D. Mieog
Ultrasound in Medicine & Biology.2019; 45(8): 2019. CrossRef
Microvascular invasion is a major prognostic factor after pancreatico‐duodenectomy for adenocarcinoma
Fabrizio Panaro, Tarek Kellil, Julie Vendrell, Valentina Sega, Regis Souche, Tullio Piardi, Piera Leon, Christophe Cassinotto, Eric Assenat, Edoardo Rosso, Francis Navarro
Journal of Surgical Oncology.2019; 120(3): 483. CrossRef
Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer
Yoonhyeong Byun, Youngmin Han, Jae Seung Kang, Yoo Jin Choi, Hongbeom Kim, Wooil Kwon, Sun‐Whe Kim, Do‐Youn Oh, Sang Hyub Lee, Ji Kon Ryu, Yong‐Tae Kim, Jin‐Young Jang
Journal of Hepato-Biliary-Pancreatic Sciences.2019; 26(9): 416. CrossRef
Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer
Lucia Roa-Peña, Cindy V. Leiton, Sruthi Babu, Chun-Hao Pan, Elizabeth A. Vanner, Ali Akalin, Jela Bandovic, Richard A. Moffitt, Kenneth R. Shroyer, Luisa F. Escobar-Hoyos
Scientific Reports.2019;[Epub] CrossRef
Comment on “The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma”
Niccolo Petrucciani, Laura Antolino, Giovanni Moschetta, Giovanni Ramacciato
Annals of Surgery.2019; 270(6): e129. CrossRef
Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer—Where Is the Least Harm and Most Benefit?
Rupaly Pandé, Keith J. Roberts
Frontiers in Oncology.2019;[Epub] CrossRef
Duktales Adenokarzinom des Pankreas
E. Gallmeier, T. M. Gress
Der Internist.2018; 59(8): 805. CrossRef
Adjuvant Chemotherapy Versus Chemoradiation for Patients with Resected Pancreatic Adenocarcinoma: A Single-Center Retrospective Study
Do Young Kim, Young Jin Choi, Young Mi Seol, Hyojeong Kim
The Korean Journal of Pancreas and Biliary Tract.2018; 23(3): 108. CrossRef
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes
Andrew McGuigan, Paul Kelly, Richard C Turkington, Claire Jones, Helen G Coleman, R Stephen McCain
World Journal of Gastroenterology.2018; 24(43): 4846. CrossRef
Combined hepatic arterial resection in pancreatic resections for locally advanced pancreatic cancer
Masaru Miyazaki, Hideyuki Yoshitomi, Shigetsugu Takano, Hiroaki Shimizu, Atsushi Kato, Hiroyuki Yoshidome, Katunori Furukawa, Tsukasa Takayashiki, Satoshi Kuboki, Daisuke Suzuki, Nozomu Sakai, Masayuki Ohtuka
Langenbeck's Archives of Surgery.2017; 402(3): 447. CrossRef
The TRIANGLE operation – radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study
Thilo Hackert, Oliver Strobel, Christoph W. Michalski, André L. Mihaljevic, Arianeb Mehrabi, Beat Müller-Stich, Christoph Berchtold, Alexis Ulrich, Markus W. Büchler
HPB.2017; 19(11): 1001. CrossRef

13,494 View
397 Download
69 Web of Science
64 Crossref

Original Articles

Radiation-Induced Sarcoma: A 15-Year Experience in a Single Large Tertiary Referral Center: Kyung Su Kim, Ji Hyun Chang, Noorie Choi, Han-Soo Kim, Ilkyu Han, Kyung Chul Moon, Il Han Kim, Hak Jae Kim; Cancer Res Treat. 2016;48(2):650-657. Published online September 9, 2015; DOI: https://doi.org/10.4143/crt.2015.171

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to report on the incidence and the experience in management of radiation-induced sarcoma (RIS) at a large single center in Korea for 15 years.
Materials and Methods
We retrospectively reviewed the sarcoma registry of a large institution from January 2000 to April 2014.
Results
Out of the 3,674 patients listed in the registry, 33 patients (0.9%) diagnosed with RIS were identified. The median latency of RIS was 12.1 years. The number of cases of RIS increased from four cases in the years 2000-2003 to 14 cases in the years 2012-2014. The most common histology was osteosarcoma (36.4%). The median follow-up period was 23.1 months, the median overall survival (OS) of all patients was 2.9 years, and their 5-year survival rate was 44.7%. Univariate and multivariate analyses showed association of the age at diagnosis (p=0.01) and the treatment aim (p=0.001) with the OS. The median OS and the 5-year survival rate of patients treated with curative surgery (n=19) were 9.6 years and 65%, respectively, and of the conservatively treated patients, 0.7 years and 0% (n=14). Re-irradiation was delivered to nine patients, and radiation toxicity was observed in five patients.
Conclusion
In this study, RIS accounted for 0.9% of the cases of sarcoma, with increasing incidence. Despite the association of curative resection with increased survival, it could be applied to only 58% of the patients. Considering the limited treatment options for RIS, conduct of a genetic study to identify the underlying mechanism of RIS is needed.

Citations

Citations to this article as recorded by

Radiation-induced osteosarcoma in the head and neck region: Case report and literature review
Iara Vieira Ferreira, Marcelo Elias Schempf Cattan, Carlos Takahiro Chone, Arthur Antolini, Erika Said Abu Egal, Albina Altemani, Fernanda Viviane Mariano
Oral Oncology.2025; 162: 107216. CrossRef
A bone tumor‐like chest wall mass lesion with pathological rib fractures observed 13 years after lung stereotactic body radiotherapy: A case report
Masaki Matsuda, Jiro Ichikawa, Takafumi Komiyama, Kojiro Onohara, Masahide Saito, Hikaru Nemoto, Mizuki Kubota, Hiroshi Onishi
Thoracic Cancer.2024; 15(26): 1912. CrossRef
The role of perioperative treatment in radiation-associated soft tissue sarcomas
Konrad Zasadziński, Mateusz Jacek Spałek
Oncologie.2024; 26(6): 1065. CrossRef
Clinical and Pathologic Characterization of 94 Radiation-Associated Sarcomas: Our Institutional Experience
Erica Y. Kao, Abbye E. McEwen, James K. Aden, Stephanie K. Schaub, Robert W. Ricciotti, Jose G. Mantilla
International Journal of Surgical Pathology.2023; 31(5): 532. CrossRef
Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study
Mauricio Fernando Ribeiro, Hagit Peretz Soroka, Zainab Bhura, Ian Hirsch, Jay Wunder, Peter Ferguson, Kim Tsoi, Savtaj Brar, Rebecca Gladdy, Carol Swallow, Peter Chung, Charles Catton, Philip Wong, Geoffrey Watson, Albiruni Ryan Abdul Razak, Abha A. Gupta
Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef
Treatment and Outcomes of Radiation-Induced Soft Tissue Sarcomas of the Extremities and Trunk—A Systematic Review of the Literature
Maria L. Inchaustegui, Kelly Kon-Liao, Kim Ruiz-Arellanos, George Aquilino E. Silva, Marcos R. Gonzalez, Juan Pretell-Mazzini
Cancers.2023; 15(23): 5584. CrossRef
Temporary Knockdown of p53 During Focal Limb Irradiation Increases the Development of Sarcomas
Andrea R. Daniel, Chang Su, Nerissa T. Williams, Zhiguo Li, Jianguo Huang, Omar Lopez, Lixia Luo, Yan Ma, Lorraine da Silva Campos, Sara R. Selitsky, Jennifer L. Modliszewski, Siyao Liu, Rosa Hernansaiz-Ballesteros, Yvonne M. Mowery, Diana M. Cardona, Cha
Cancer Research Communications.2023; 3(12): 2455. CrossRef
Treatment related factors associated with the risk of breast radio-induced-sarcoma
Céline Mirjolet, Ibrahima Diallo, Aurélie Bertaut, Cristina Veres, Paul Sargos, Sylvie Helfre, Marie-Pierre Sunyach, Gilles Truc, Cécile Le Pechoux, Amaury Paumier, Anne Ducassou, Maria Jolnerovski, Juliette Thariat, Michel Lapeyre, Abel Cordoba, Marc-And
Radiotherapy and Oncology.2022; 171: 14. CrossRef
Radiation-induced osteosarcoma in the pubic bone after proton radiotherapy for prostate cancer: a case report
Hiroatsu Nakashima, Tetsuro Takatsu, Reiko Imai
Journal of Rural Medicine.2022; 17(2): 94. CrossRef
Premalignant Conditions of Bone
Michael D. Eckhoff, Matthew E. Wells, Osvaldo Padilla, Elizabeth M. Polfer, Christopher J. Castagno, Ahmed M. Thabet, Shaimaa Elzamly, Harry L. Wilson, Rajiv Rajani
JAAOS: Global Research and Reviews.2022;[Epub] CrossRef
Histology-Specific Prognostication for Radiation-Associated Soft Tissue Sarcoma
Edmund K. Bartlett, Avinash Sharma, Kenneth Seier, Cristina R. Antonescu, Narasimhan P. Agaram, Bhumika Jadeja, Evan Rosenbaum, Ping Chi, Murray F. Brennan, Li-Xuan Qin, Kaled M. Alektiar, Samuel Singer
JCO Precision Oncology.2022;[Epub] CrossRef
Radiation-induced soft tissue sarcoma of the neck after radiation therapy for Hodgkin's lymphoma: a clinical case
Nikolai A. Ognerubov, Tatiana S. Antipova
Journal of Modern Oncology.2022; 24(3): 325. CrossRef
Prognostic Score-Based Stratification Analysis Reveals Universal Benefits of Radiotherapy on Lowering the Risk of Ipsilateral Breast Event for Ductal Carcinoma In Situ Patients with Different Risk Levels
Libo Yang, Dongli Lu, Yutian Lai, Mengjia Shen, Qiuxiao Yu, Ting Lei, Tianjie Pu, Hong Bu
Annals of Surgical Oncology.2021; 28(2): 975. CrossRef
Radiation-Induced Sarcomas of the Head and Neck: A Systematic Review
Andrés Coca-Pelaz, Antti A. Mäkitie, Primož Strojan, June Corry, Avraham Eisbruch, Jonathan J. Beitler, Sandra Nuyts, Robert Smee, Johannes A. Langendijk, William M. Mendenhall, Cesare Piazza, Alessandra Rinaldo, Alfio Ferlito
Advances in Therapy.2021; 38(1): 90. CrossRef
En bloc resection and reconstruction in patients with advanced recurrent nasopharyngeal carcinoma and radiation-induced sarcoma of the head and neck
W.-l. Chen, Y.-M. Liu, B. Zhou, R. Chen, Z.-y. Lin, Z.-q. Huang, Z-x. Huang
International Journal of Oral and Maxillofacial Surgery.2021; 50(6): 711. CrossRef
Incidence of radiation induced sarcoma attributable to radiotherapy in adults: A retrospective cohort study in the SEER cancer registries across 17 primary tumor sites
Anson Snow, Alexander Ring, Lucas Struycken, Wendy Mack, Melissa Koç, Julie E. Lang
Cancer Epidemiology.2021; 70: 101857. CrossRef
Radiation-Induced Sarcoma: A Retrospective Population-Based Study Over 34 Years in a Single Institution
L.B. Callesen, A. Safwat, H.K. Rose, F.B. Sørensen, T. Baad-Hansen, N. Aggerholm-Pedersen
Clinical Oncology.2021; 33(5): e232. CrossRef
Proliferating trichilemmal tumour of the eyelid in a 7-year-old girl
Avery Bryan, Susan Kurian, Yan Li, Paige Bundrick
BMJ Case Reports.2021; 14(2): e237476. CrossRef
Treating radiation-induced sarcoma of the head and neck: A case report
Yuka Takumi, Kazufumi Obata, Atsushi Kondo, Ryo Miyata, Ayaka Sasaki, Kenichi Takano
Otolaryngology Case Reports.2021; 19: 100283. CrossRef
Pelvic Radiation-Induced Sarcoma With Rhabdomyoblastic Differentiation Following Treatment of Cervical Cancer
Shahd S Almohsen, Hala Alnuaim, Alaa A Salim, Haitham Arabi
Cureus.2021;[Epub] CrossRef
MYC expression has limited utility in the distinction of undifferentiated radiation‐associated sarcomas from sporadic sarcomas and sarcomatoid carcinoma
Jeffrey K Mito, Xiaohua Qian, Vickie Y Jo, Leona A Doyle
Histopathology.2020; 77(4): 667. CrossRef
Sarcomas óseos secundarios
J.-C. Mattei, A. Griffin, P. Ferguson, G. Venton, J. Wunder, A. Rochwerger
EMC - Aparato Locomotor.2020; 53(4): 1. CrossRef
Sarcomes osseux secondaires
J.-C. Mattei, A. Griffin, P. Ferguson, G. Venton, J. Wunder, A. Rochwerger
EMC - Appareil locomoteur.2020; 34(3): 1. CrossRef
Radiation-Associated Sarcomas
Jeffrey K. Mito, Devarati Mitra, Leona A. Doyle
Surgical Pathology Clinics.2019; 12(1): 139. CrossRef
A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas
Jeffrey K. Mito, Devarati Mitra, Constance M. Barysauskas, Adrián Mariño-Enriquez, Elizabeth A. Morgan, Christopher D.M. Fletcher, Chandrajit P. Raut, Elizabeth H. Baldini, Leona A. Doyle
International Journal of Radiation Oncology*Biology*Physics.2019; 104(2): 425. CrossRef
Osteosarcoma of the jaw – experience at the Medical University Vienna and comparative study with international tumor registries
Christina Eder-Czembirek, Doris Moser, Simone Holawe, Thomas Brodowicz, Jutta Ries, Irene Sulzbacher, Edgar Selzer
Clinics.2019; 74: e701. CrossRef
Multifocal superficial rapidly growing postirradiation sarcoma mimicking metastatic carcinoma
Debasis Gochhait, Priyadarshini Dehuri, Vidhyalakshmi Rangarajan, Neelaiah Siddaraju
Journal of Mid-life Health.2019; 10(2): 101. CrossRef
Radiation-induced sarcoma in a cat following hypofractionated, palliative intent radiation therapy for large-cell lymphoma
Matthew R Cook, Michael P Martinez, Joelle M Fenger, Noopur C Desai
Journal of Feline Medicine and Surgery Open Reports.2019;[Epub] CrossRef
Unique Case Report of a Meningeal Sarcoma Arising during Ongoing Treatment for Progressing Intraparenchymal Glioma
Richard A. Peterson, Bhavani Kashyap, Pamala A. Pawloski, Anna C. Forsberg, Leah R. Hanson
Case Reports in Oncological Medicine.2019; 2019: 1. CrossRef
Radiation‐associated sarcoma after breast cancer in a nationwide population: Increasing risk of angiosarcoma
Samuli H. Salminen, Mika M. Sampo, Tom O. Böhling, Laura Tuomikoski, Maija Tarkkanen, Carl P. Blomqvist
Cancer Medicine.2018; 7(9): 4825. CrossRef
Radiation-Associated Sarcoma of the Neck: Case Series and Systematic Review
Lawrence Williams, Lyubov Tmanova, Wojciech K. Mydlarz, Brandi Page, Jeremy D. Richmon, Harry Quon, Nicole C. Schmitt
Annals of Otology, Rhinology & Laryngology.2018; 127(10): 735. CrossRef
Radiation‐associated neoplasia: clinical, pathological and genomic correlates
Lynette M Sholl, Justine A Barletta, Jason L Hornick
Histopathology.2017; 70(1): 70. CrossRef
Magnetic Resonance Imaging of Soft Tissue Masses
Aaron D. Fain, Francesca D. Beaman
Seminars in Roentgenology.2017; 52(4): 227. CrossRef
Characteristics of tumors that have developed in mice injected with syngenic irradiated mesenchymal stem cells of bone marrow
E. Yu. Moskaleva, E. S. Zhorova, Yu. P. Semochkina, A. V. Rodina, O. V. Vysotskaya, A. I. Glukhov, A. A. Chukalova, G. A. Posypanova, V. P. Saprykin
Cell and Tissue Biology.2017; 11(5): 381. CrossRef
Case Report: Primary De Novo Sarcoma In Transplant Pancreas Allograft
S. Nagaraju, S.J. Grethlein, S. Vaishnav, A.A. Sharfuddin, J.A. Powelson, J.A. Fridell
Transplantation Proceedings.2017; 49(10): 2352. CrossRef
Radiation-induced osteosarcoma of the maxilla and mandible after radiotherapy for nasopharyngeal carcinoma
Lie-Qiang Liao, Hong-Hong Yan, Jun-Hao Mai, Wei-Wei Liu, Hao Li, Zhu-Ming Guo, Zong-Yuan Zeng, Xue-Kui Liu
Chinese Journal of Cancer.2016;[Epub] CrossRef

14,524 View
198 Download
29 Web of Science
36 Crossref

Objective Measurement of Cosmetic Outcomes of Breast Conserving Therapy Using BCCT.core: Tosol Yu, Keun-Yong Eom, Na Young Jang, Kyung Su Kim, Tae Ryool Koo, Jeanny Kwon, Byoung Hyuck Kim, Eunyoung Kang, Sung-Won Kim, Jae-Sung Kim, In Ah Kim; Cancer Res Treat. 2016;48(2):491-498. Published online June 22, 2015; DOI: https://doi.org/10.4143/crt.2015.088

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study is to evaluate objective cosmetic outcomes and factors related to breast-conserving therapy (BCT) using the BCCT.core software.
Materials and Methods
Fifty-one patients who received BCT with informed consent were evaluated using the BCCT.core software. Patients were divided into two groups based on the BCCT score: excellent or good (n=42) vs. fair or poor (n=9). Analysis of clinical factors was performed to determine factors affecting cosmetic outcomes.
Results
The objective cosmetic outcome of BCT measured using the BCCT.core software was excellent in 10% of patients, good in 72%, and fair in 18%. None of the patients were classified as poor outcome. Tumor characteristics, systemic adjuvant therapy (chemotherapy and hormonal therapy), and radiation dose or energy of electron boost did not show correlation with the score measured by the BCCT.core program (p > 0.05). In univariate analysis, maximum dose within the breast (Dmax), width of tangential field, and excised tumor volume were smaller in patients with excellent or good by the BCCT.core compared to those with fair or poor (Dmax, 110.2±1.5% vs. 111.6±1.7%, p=0.019; width of tangential field, 8.0±1.1 cm vs. 8.6±0.7 cm, p=0.034; excised tumor volume, 64.0±35.8 cm3 vs. 95.3±54.4 cm3, p=0.067). In multivariate analysis, only Dmax was a significant factor for breast cosmetic outcome with a risk ratio of 1.697 (95% confidence interval, 1.006 to 2.863; p=0.047).
Conclusion
Objective measurement of cosmetic outcome of BCT using the BCCT.core software was feasible. The cosmetic outcome of BCT may be affected by the maximum dose within the breast.

Citations

Citations to this article as recorded by

Impact of autologous breast reconstruction on bra fit
Yen-Tung Liu, Novera H. Khan, Mary Catherine Bordes, Gregory P. Reece, Ashleigh M. Francis, Tzuan A. Chen, Karen Bravo, Mia K. Markey
Supportive Care in Cancer.2024;[Epub] CrossRef
Easy Anthropometric Measurements Are Representative of Baseline Values of Breast Q Values in Asymptomatic Women
Giuseppe Catanuto, Nicola Rocco, Concetta G. Fichera, Ada Cinquerrui, Martina Rapisarda, Paolo Chiodini, Francesca Magnoni, Patrizia Dorangricchia, Valeria Sebri, Gabriella Pravettoni, Maurizio Bruno Nava, Francesco Caruso
Healthcare.2024; 12(2): 268. CrossRef
Identification of Key Breast Features Using a Neural Network: Applications of Machine Learning in the Clinical Setting of Plastic Surgery
Nitzan Kenig, Javier Monton Echeverria, Luis De la Ossa
Plastic & Reconstructive Surgery.2024; 153(2): 273e. CrossRef
Outcomes of reconstructive techniques in breast cancer using BCCT. core software
Sevgi Kurt, Ahmet Serkan İlgün, Enver Özkurt, Gürsel Soybir, Gül Alço, Çağlar Ünal, Filiz Elbüken Çelebi, Tomris Duymaz, Tuğba Kayan Tapan, Naziye Ak, Çetin Ordu, Vahit Özmen
World Journal of Surgical Oncology.2024;[Epub] CrossRef
Evaluating intra and inter-observer bias in the cosmetic rating for random vs. serial assessment of breast photographs
Preeti Belani, Rima Pathak, Shraddha Kenekar, Gaurika Pokale, Pallavi Rane, Ashwini Chalke, Tabassum Wadasadawala
The Royal College of Radiologists Open.2024; 2: 100152. CrossRef
Comparison of Postoperative Breast Asymmetry Using Vectra 3D Imaging in Prepectoral Versus Subpectoral Implant-Based Breast Reconstruction
Seung-Ho Choi, Sang-Oh Lee, Kyu-Jin Chung, Il-Kug Kim, Jun-Ho Lee
Journal of Clinical Medicine.2024; 13(23): 7486. CrossRef
Long-term Efficacy and Cosmetic Outcomes of Partial-breast Irradiation Using Multicatheter Interstitial Brachytherapy for Breast-conserving Therapy
Kazuhiko SATO, Hiromi FUCHIKAMI, Naoko TAKEDA, Nana NATSUME, Masahiro KATO
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2023; 84(2): 238. CrossRef
Breast cancer patient-reported outcome of factors influencing cosmetic satisfaction after breast-conserving therapy
A. T. P. M. Brands-Appeldoorn, A. J. G. Maaskant-Braat, L. Janssen, L. A. D. M. van Osch, V. C. G. Tjan-Heijnen, R. M. H. Roumen
Breast Cancer.2022; 29(1): 114. CrossRef
BROWSE: A multicentre comparison of nine year outcomes in acellular dermal matrix based and complete submuscular implant-based immediate breast reconstruction-aesthetics, capsular contracture and patient reported outcomes
Rebecca L. Wilson, Cliona C. Kirwan, Joe M. O'Donoghue, Richard A. Linforth, Richard K. Johnson, James R. Harvey
European Journal of Surgical Oncology.2022; 48(1): 73. CrossRef
Factors related to patient-reported cosmetic outcome after breast-conserving therapy for breast cancer
A. T. P. M. Brands-Appeldoorn, R. C. M. Thomma, L. Janssen, A. J. G. Maaskant-Braat, V. C. G. Tjan-Heijnen, R. M. H. Roumen
Breast Cancer Research and Treatment.2022; 191(3): 545. CrossRef
Adaptation of BCCT Learning Model in Developing Religious Aspects of Children
Abd Hamid Wahid, Muhammad Fajri, Hasan Baharun, Riana Imroatul Fitriyah, Arifatur Risqiyah
Jurnal Obsesi : Jurnal Pendidikan Anak Usia Dini.2022; 6(4): 3439. CrossRef
Methods of Esthetic Assessment after Adjuvant Whole-Breast Radiotherapy in Breast Cancer Patients: Evaluation of the BCCT.core Software and Patients’ and Physicians’ Assessment from the Randomized IMRT-MC2 Trial
Tobias Forster, Clara Köhler, Melissa Dorn, Matthias Felix Häfner, Nathalie Arians, Laila König, Semi Ben Harrabi, Ingmar Schlampp, Eva Meixner, Vanessa Heinrich, Nicola Weidner, Michael Golatta, André Hennigs, Jörg Heil, Holger Hof, David Krug, Jürgen De
Cancers.2022; 14(12): 3010. CrossRef
Feasibility of anomaly score detected with deep learning in irradiated breast cancer patients with reconstruction
Dong-Yun Kim, Soo Jin Lee, Eun-Kyu Kim, Eunyoung Kang, Chan Yeong Heo, Jae Hoon Jeong, Yujin Myung, In Ah Kim, Bum-Sup Jang
npj Digital Medicine.2022;[Epub] CrossRef
Breast Oncoplastic Resections: No Innovation Without Evaluation
Sherif Monib, Mohamed Farag, Mohamed Ibrahim
Indian Journal of Surgery.2021; 83(S2): 409. CrossRef
Cosmetic Outcomes of a Phase 1 Dose Escalation Study of 5-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast Cancer
Asal Rahimi, Howard E. Morgan, Dong W. Kim, Yuanyuan Zhang, Marilyn Leitch, Rachel Wooldridge, Sally Goudreau, Barbara Haley, Roshni Rao, Aeisha Rivers, Ann E. Spangler, Ryan T. Jones, Stella Stevenson, Jason Staley, Kevin Albuquerque, Chul Ahn, Sarah Neu
International Journal of Radiation Oncology*Biology*Physics.2021; 110(3): 772. CrossRef
Comparative study between laparoscopically harvested omental flap and glandular flap in immediate reconstruction after conservative surgery in breast cancer
Waleed Y. El‐Sherpiny, Abdulhamid M. Abdelshafi, Mohamed Ghazaly, Ayman A. Elnemr, Ahmed A. Darwish, Mohamed A. Mlees
Surgical Practice.2021; 25(2): 92. CrossRef
Reliability of the BCCT.core software in evaluation of breast cosmesis – A systematic review
Stami Trakis, Heidi Lord, Peter Graham, Ritin Fernandez
Journal of Medical Imaging and Radiation Oncology.2021; 65(6): 817. CrossRef
New criteria for breast symmetry evaluation after breast conserving surgery for cancer
RENÉ ALOISIO DA COSTA VIEIRA, GABRIELE BILLER, FABIOLA CRISTINA BRANDINI DA SILVA, JONATHAS JOSÉ DA SILVA, MARCO ANTÔNIO DE OLIVEIRA, ANTÔNIO BAILÃO-JUNIOR
Revista do Colégio Brasileiro de Cirurgiões.2021;[Epub] CrossRef
Use of Symmetry Assessment Methods in the Context of Breast Surgery
Javier Monton, Asia Torres, Maria Gijon, Luis Chang-Azancot, Nitzan Kenig, P. Camelia Trandafir, Joaquin Jordan, Ricardo Insausti
Aesthetic Plastic Surgery.2020; 44(5): 1440. CrossRef
Visual Breast Asymmetry Assessment with Optical-Flow Algorithm
Javier Monton, Nitzan Kenig, Ricardo Insausti, Joaquin Jordan
Journal of Medical Systems.2020;[Epub] CrossRef
Nueva metodología para medir simetría frontal en pacientes reconstruidas por cáncer de mama
Lenia Sánchez Wals, Carlos Acosta-Batista, Oscar Luis Vera Pérez, Juan Jesús Lence Anta, Marco Marcasciano
Revista de Senología y Patología Mamaria.2019; 32(4): 133. CrossRef
Objective assessment of flap volume changes and aesthetic results after adjuvant radiation therapy in patients undergoing immediate autologous breast reconstruction
Yujin Myung, Yousung Son, Tae-hyun Nam, Eunyoung Kang, Eun-Kyu Kim, In Ah Kim, Keun-Yong Eom, Chan Yeong Heo, Jae Hoon Jeong, Fabio Santanelli, di Pompeo d'Illasi
PLOS ONE.2018; 13(5): e0197615. CrossRef

21,954 View
122 Download
21 Web of Science
22 Crossref

First
Prev
Page of 1
Next
Last

Search